查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
中樞神經系統藥物市場 2022-2028
市場調查報告書
商品編碼
1215776

中樞神經系統藥物市場 2022-2028

Central Nervous System Therapeutic Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 | 商品交期: 2-3個工作天內

價格

在預測期內，全球中樞神經系統治療市場預計將以 7.5% 的複合年增長率增長。 全球神經系統疾病患病率上升導致中樞神經系統治療全球市場增長率加快。 根據世界衛生組織 (WHO) 的數據，全世界有超過 5000 萬人患有癲癇症。 此外，據估計全世界有4750萬癡呆症患者，每年有770萬人新診斷為癡呆症。 阿爾茨海默氏病是癡呆症最常見的原因，據信佔 60-70% 的病例。 此外，全世界偏頭痛的患病率超過 10%。 這正在加速對這些疾病治療的需求並推動市場增長。

全球中樞神經系統治療市場根據適應症、用途和藥物類別進行細分。 根據適應症，市場分為神經血管疾病、中樞神經系統創傷、心理健康、神經退行性疾□□病、傳染病、癌症等。 按用途分為醫院/診所、家庭醫療和其他。 按藥物類別，市場分為免疫調節劑、干擾素、脫羧□抑製劑、多巴胺激動劑、抗抑鬱藥等。 以上分區可根據您的要求定制。 免疫調節劑用於抑制免疫系統並幫助身體抵抗感染、癌症和其他疾病。

內容

第 1 章報告概述

  • 當前行業分析和增長前景
  • 全球中樞神經系統藥物市場的複蘇情景
  • 研究方法和工具
  • 市場細分
    • 按細分
    • 按地區

第 2 章市場概述和洞察

  • 調查範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 推薦
    • 總結

第三章競爭格局

  • 主要公司分析
    • 強生服務公司
    • 默克公司
    • 諾華公司
    • 百健公司
    • 禮來公司
  • 關鍵策略分析

第四章市場細分

  • 全球中樞神經系統藥物市場：按適應症分類
    • 神經血管疾病
    • 中樞神經系統創傷
    • 心理健康
    • 神經退行性疾□□病
    • 感染
    • 癌症
  • 全球中樞神經系統藥物市場：按應用分類
    • 醫院和診所
    • 家庭護理
    • 其他
  • 全球中樞神經系統藥物市場：按藥物類別分類
    • 免疫調節劑
    • 干擾素
    • 脫羧□抑製劑
    • 多巴胺激動劑
    • 抗抑鬱藥
    • 其他

第五章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 世界其他地方

第六章公司簡介

  • AstraZeneca plc
  • Cipla Ltd.
  • CNS Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Lupin Ltd.
  • Medopharm Private Ltd.
  • Neurelis, Inc.
  • Nuventra Pharma Sciences
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Shire plc
  • Teva Pharmaceutical Industries Ltd.
Product Code: OMR2026832

Title:Global Central Nervous System Therapeutic Market Size, Share and Trends Analysis Report, By Indication (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, and Cancer), By Application (Hospital and Clinic, Homecare, and Others), By Drug Class (Immunomodulatory Drugs, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Antidepressants, and Others), Forecast Period (2022-2028).

The global central nervous system therapeutics market is anticipated to grow at a CAGR of 7.5% during the forecast period. The rising prevalence of neurological disorders across the globe is leading to the increasing growth of the global central nervous system therapeutic market. According to the World Health Organization (WHO), over 50 million people have epilepsy globally. It is estimated that there are globally 47.5 million people with dementia with 7.7 million new cases every year. Alzheimer's disease is the most common cause of dementia and may contribute to 60-70% of cases. The prevalence of migraine is more than 10% across the globe. This, in turn, is accelerating the demand for the treatment of these conditions, thereby driving market growth.

The global central nervous system therapeutics market is segmented based on indication, application, and drug class. Based on the indication, the market is segmented into neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases, and cancer. Based on the application, the market is segmented into hospitals & clinics, homecare, and others. Based on drug class, the market is segmented into immunomodulatory drugs, interferons, decarboxylase inhibitors, dopamine agonists, antidepressants, and others. The above-mentioned segments can be customized as per the requirements. Immunomodulatory drugs are used as it suppresses the immune system and supports the body to fight infection, cancer and other diseases.

The global central nervous system therapeutic market is segmented based on geography including North America (the US and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa and Latin America). The market can be analyzed for a particular region or country level as per the requirement. North American region is expected to hold a significant share in the global CNS therapeutic market, owing to the rising incidence of neurodegenerative disorders such as brain tumor in the region. According to the American Cancer Society, latest data in 2022 around 25,050 malignant tumors of the brain or spinal cord will be diagnosed in the US and around 18,280 people will die from the brain and spinal cord tumors.

The major companies serving the global central nervous system therapeutic market include Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Biogen Inc., and Eli Lilly, and Company Inc. The market players are contributing to the market growth through the adoption of various strategies including mergers and acquisitions, collaborations, and new product launches, to stay competitive in the market. For instance, in May 2022, Biogen Inc. and Denali Therapeutics Inc. announced the initiation of phase 2b study of LRRK2 Inhibitor in Parkinson's Disease which is a central nervous disease that will slow down the progression of Parkinson's disease.

Research Methodology

The market study of the global central nervous system therapeutic market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Central Nervous System Therapeutic Market Research and Analysis by Indication
  • Global Central Nervous System Therapeutic Market Research and Analysis by Application
  • Global Central Nervous System Therapeutic Market Research and Analysis by Drug Class

The Report Covers:

  • Comprehensive research methodology of the global central nervous system therapeutic market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global central nervous system therapeutic market.
  • Insights about market determinants that are stimulating the global central nervous system therapeutic market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Recovery Scenario of Global Central Nervous System Therapeutic Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Johnson & Johnson Services Inc.
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. Merck & Co. Inc.
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Novartis AG
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. Biogen Inc.
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
    • 3.1.5. Eli Lilly and Company Inc.
      • 3.1.5.1. Overview
      • 3.1.5.2. Financial Analysis
      • 3.1.5.3. SWOT Analysis
      • 3.1.5.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Central Nervous System Therapeutics Market by Indication
    • 4.1.1. Neurovascular Diseases
    • 4.1.2. CNS Trauma
    • 4.1.3. Mental Health
    • 4.1.4. Neurodegenerative Diseases
    • 4.1.5. Infectious Diseases
    • 4.1.6. Cancer
  • 4.2. Global Central Nervous System Therapeutic Market by Application
    • 4.2.1. Hospitals and Clinics
    • 4.2.2. Homecare
    • 4.2.3. Others
  • 4.3. Global Central Nervous System Therapeutic Market by Drug Class
    • 4.3.1. Immunomodulatory Drugs
    • 4.3.2. Interferons
    • 4.3.3. Decarboxylase Inhibitors
    • 4.3.4. Dopamine Agonists
    • 4.3.5. Antidepressants
    • 4.3.6. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AstraZeneca plc
  • 6.2. Cipla Ltd.
  • 6.3. CNS Pharmaceuticals, Inc.
  • 6.4. F. Hoffmann-La Roche Ltd.
  • 6.5. GlaxoSmithKline plc
  • 6.6. H. Lundbeck A/S
  • 6.7. Lupin Ltd.
  • 6.8. Medopharm Private Ltd.
  • 6.9. Neurelis, Inc.
  • 6.10. Nuventra Pharma Sciences
  • 6.11. Otsuka Pharmaceutical Co., Ltd.
  • 6.12. Pfizer Inc.
  • 6.13. Sanofi S.A.
  • 6.14. Shire plc
  • 6.15. Teva Pharmaceutical Industries Ltd.

LIST OF TABLES

  • 1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
  • 2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEUROVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CNS TRAUMA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR MENTAL HEALTH MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEURODEGENERATIVE DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOMECARE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 13. GLOBAL IMMUNOMODULATORY DRUGS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBAL INTERFERONS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBAL DECARBOXYLASE INHIBITORS CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 16. GLOBAL DOPAMINE AGONISTS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 17. GLOBAL ANTIDEPRESSANTS CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 18. GLOBAL OTHER DRUG CLASS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 19. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 20. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 21. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
  • 22. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 23. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 24. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 25. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
  • 26. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 27. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 28. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 29. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
  • 30. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 31. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 32. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 33. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
  • 34. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 35. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)

 

LIST OF FIGURES

  • 1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEURODEGENERATIVE DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY INDICATION, 2021 VS 2028 (%)
  • 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEUROVASCULAR DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CNS TRAUMA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR MENTAL HEALTH MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEURODEGENERATIVE DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR INFECTIOUS DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOSPITAL & CLINIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOMECARE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR OTHERS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY DRUG CLASS, 2021 VS 2028 (%)
  • 14. GLOBAL IMMUNOMODULATORY DRUGS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. GLOBAL INTERFERONS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 16. GLOBAL DECARBOXYLASE INHIBITORS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 17. GLOBAL DOPAMINE AGONISTS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 18. GLOBAL ANTIDEPRESSANTS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 19. GLOBAL OTHER DRUG CLASS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 20. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 21. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. UK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. REST OF EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 31. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 32. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 33. REST OF ASIA-PACIFIC CENTRAL NERVOUS SYSTEMTHERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 34. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)